Reprogene is a state-of-the-art clinical genetics facility independently and privately owned in the United States. We help individuals make informed clinical genomic related decisions to benefit their wellbeing, and provide early predictive genomic alternatives to improve the health of future generations. Utilizing the latest technologies and genetic testing, we educate individuals to make customized and proactive health choices.

 

Our up to date genomic tests are able to detect human chromosomal abnormalities, and inherited genetic diseases even at an embryonic stage. For over a decade, Reprogene has been leading the field in providing specialized clinical genomic tests, and covering all major medical disciplines; including: clinical genomics, reproductive genomics, prenatal genomics, oncology, personalized genomics medicine, general health and wellness genomics, female fertility health, sperm health and male fertility. Accuracy and reliability are the characteristics that signify our results and analysis. With our continuous engagement in research and development (R&D), Reprogene eliminated several of the last drawbacks of IVF treatment increasing its success rate by far to its highest.  The organization is always devoted to innovate and progress to meet the evolving needs of clinical genomics field. Our headquarters are conveniently located in Mission Viejo, California, since the facility was founded in 2005. We imprinted global presence in 2016 by opening our hub for Europe, Middle East and Africa (EMEA) in Amman, Jordan, to reach our vision and fulfill our mission. Multiple international accreditations (ISO, CAP, CLIA, AAB, ABB, ABMGG, JAS, and JCIA) verify our utmost credibility and reflect on our global organizational values. With international recognition through patented technologies and a growing number of clients, Reprogene always maintains the most innovative technologies to keep up with global demands.